Key Insights

Highlights

Success Rate

98% trial completion (above average)

Published Results

107 trials with published results (49%)

Research Maturity

192 completed trials (88% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

1.4%

3 terminated out of 219 trials

Success Rate

98.5%

+12.0% vs benchmark

Late-Stage Pipeline

70%

153 trials in Phase 3/4

Results Transparency

56%

107 of 192 completed with results

Key Signals

107 with results98% success

Data Visualizations

Phase Distribution

201Total
Not Applicable (8)
P 1 (14)
P 2 (26)
P 3 (106)
P 4 (47)

Trial Status

Completed192
Unknown12
Active Not Recruiting4
Terminated3
Not Yet Recruiting3
Recruiting3

Trial Success Rate

98.5%

Benchmark: 86.5%

Based on 192 completed trials

Clinical Trials (219)

Showing 20 of 20 trials
NCT07492303Phase 1Not Yet Recruiting

A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)

NCT07444502Completed

Safety Monitoring of Boostagen® Vaccine in Thailand

NCT07418372Phase 1Not Yet Recruiting

Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine

NCT03891758Phase 3Completed

Confirmatory Study of BK1310 in Healthy Infants

NCT02118961Phase 3CompletedPrimary

Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents

NCT06588530Phase 4Completed

PFAS Exposure and Immune Response to Vaccination in Adults

NCT05091619Phase 3Active Not Recruiting

A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed

NCT06947499Phase 2RecruitingPrimary

A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series

NCT03589768Phase 2Completed

Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants

NCT06056050Phase 1Active Not RecruitingPrimary

A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)

NCT04061382Completed

Sero-epidemiological Survey of England in 2019/2020 - COVID-19

NCT06708286Phase 2Active Not RecruitingPrimary

A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)

NCT06618196Phase 2Not Yet RecruitingPrimary

Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age

NCT06605755Not ApplicableRecruiting

Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants

NCT04535037Phase 4CompletedPrimary

A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers

NCT02569879CompletedPrimary

Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia.

NCT05480462Phase 3Active Not RecruitingPrimary

Immunogenicity and Safety of Vaccine Against Tetanus and Diphtheria.

NCT06184542Phase 1RecruitingPrimary

Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine

NCT05952596Phase 1UnknownPrimary

A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults

NCT02458183Phase 3CompletedPrimary

Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS

Scroll to load more

Research Network

Activity Timeline